ArticleWorld journal of gastrointestinal surgery2024
Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis.
Article in World journal of gastrointestinal surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Inflammatory bowel disease and breast cancer: epidemiological evidence, shared biology, and clinical management.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Oncostatin M as a Complementary Non-Invasive Marker of Endoscopic and Histological Disease Activity in Ulcerative Colitis.International journal of molecular sciences · 2026Article
- Practical Use of Advanced AI Frameworks on Real-Life Scientific Problems: Three Case Studies.bioRxiv : the preprint server for biology · 2026Article
- TENTACLES: a consensus machine learning tool for robust biomarker discovery in heterogeneous data.BioData mining · 2026Article
- The Dual Nature of Oncostatin M: Context-Dependent Mediator of Immunity and Fibrosis.Cell biochemistry and biophysics · 2026Review
- Serum Oncostatin M in Ulcerative Colitis Patients and Its Relation to Disease Activity.International journal of molecular sciences · 2025Article
- Precision Medicine in Disorders of Gut-Brain Interaction.Gastroenterology & hepatology · 2025Article
- Association of alterations in transcriptomics and intestinal immune responses with Bifidobacterium longum BAA2573 in improving dextran sulfate sodium-induced colitis.BMC gastroenterology · 2025Article
- Drug Repurposing to Inhibit Oncostatin M in Crohn's Disease.Molecules (Basel, Switzerland) · 2025Article
- Precision Medicine in Inflammatory Bowel Disease: A Spotlight on Emerging Molecular Biomarkers.Biomedicines · 2024Review
- Diagnostic Procedures for Inflammatory Bowel Disease: Laboratory, Endoscopy, Pathology, Imaging, and Beyond.Diagnostics (Basel, Switzerland) · 2024Review
- Inflammatory Bowel Disease: A Comprehensive Analysis of Molecular Bases, Predictive Biomarkers, Diagnostic Methods, and Therapeutic Options.International journal of molecular sciences · 2024Review
- Cytokine Profile in Predicting the Effectiveness of Advanced Therapy for Ulcerative Colitis: A Narrative Review.Biomedicines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOncostatin M (OSM) is a pleiotropic cytokine which is implicated in the pathogenesis of inflammatory bowel disease (IBD).
aimTo evaluate the prognostic role of OSM in IBD patients.
methodsLiterature search was conducted in electronic databases (Google Scholar, Embase, PubMed, Science Direct, Springer, and Wiley). Studies were selected if they reported prognostic information about OSM in IBD patients. Outcome data were synthesized, and meta-analyses were performed to estimate standardized mean differences (SMDs) in OSM levels between treatment responders and non-responders and to seek overall correlations of OSM with other inflammatory biomarkers.
resultsSixteen studies (818 Crohn's disease and 686 ulcerative colitis patients treated with anti-tumor necrosis factor-based therapies) were included. OSM levels were associated with IBD severity. A meta-analysis found significantly higher OSM levels in non-responders than in responders to therapy [SMD 0.80 (0.33, 1.27);
conclusionOSM is a potential candidate for determining the severity of disease and predicting the outcomes of anti-tumor necrosis factor-based therapies in IBD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.